News | Stents Carotid | October 15, 2021

CGuard Embolic Prevention Carotid Stent Receives French Reimbursement Approval 

U.S. trial for device is also starting

 

The InspireMD CGuard Embolic Prevention Stent System (EPS) device for the treatment of carotid artery disease (CAD) and stroke prevention has received reimbursement in France from the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDIMTS) of the French National Authority for Health (HAS).

October 15, 2021 — The InspireMD CGuard Embolic Prevention Stent System (EPS) device for the treatment of carotid artery disease (CAD) and stroke prevention has received reimbursement in France from the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDIMTS) of the French National Authority for Health (HAS). The CGuard EPS is being added to the list of reimbursed medical products (LPPR) effective Oct. 25, 2021. 

This was the final step to full commercial launch of CGuard EPS following CNEDIMTS’ positive opinion for reimbursement received by the company on May 11, 2021, for the treatment of symptomatic and non-symptomatic lesions when surgery is not indicated.

The CGuard EPS Self-Expanding Carotid Stent is the latest generation open-cell nitinol self-expanding stent with patented MicroNet mesh technology designed to prevent the risk of early and late embolism.

“This milestone now provides physicians in France with the choice to use CGuard EPS in the treatment of carotid artery disease and stroke prevention. We strive to improve the standard of care in the treatment of carotid artery disease, by moving away from surgical endarterectomy towards less invasive options such as the CGuard EPS Carotid Stent System. We believe that the unique and proprietary design of our system, is the most advanced and safest stent system on the market today,” said Marvin Slosman, CEO of InspireMD.

The CGuard carotid stent is commercially established in 33 markets. 

The device is currently undergoing the C-Guardians U.S. pivotal trial to seek FDA clearance (ClinicalTrials.gov Identifier: NCT04900844).

For more information: www.inspiremd.com

Find more stroke technology news


Related Content

News | Stents

Oct. 16, 2024 — Sahajanand Medical Technologies (SMT) recently announced the publication of the COMPARE 60/80 HBR trial ...

Home October 16, 2024
Home
News | Stents

June 12, 2024 — Royal Philips, a global leader in health technology, announced the first implant of the Duo Venous Stent ...

Home June 12, 2024
Home
News | Stents

June 4, 2024 — A patient at HonorHealth Research Institute is one of the nation’s first — and the first in Arizona and ...

Home June 04, 2024
Home
News | Stents

April 17, 2024 — Getinge and Cook Medical announced an exclusive sales and distribution agreement for the iCast covered ...

Home April 17, 2024
Home
News | Stents

March 8, 2024 — Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact ...

Home March 08, 2024
Home
News | Stents

January 19, 2024 — W. L. Gore & Associates, Inc. announced that the first patients have been enrolled in the Gore VBX ...

Home January 19, 2024
Home
News | Stents

November 29, 2023 — InspireMD, Inc., developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of ...

Home November 29, 2023
Home
News | Stents

July 27, 2023 — Abiomed is recalling the Impella Intravascular Left Sided Blood Pumps because the pump’s Instructions ...

Home July 27, 2023
Home
News | Stents

June 13, 2023 — W. L. Gore & Associates (Gore) announced the initiation of the Gore VBX FORWARD Clinical Study ...

Home June 13, 2023
Home
News | Stents

March 5, 2023 — In patients with multi-vessel heart disease who have had a heart attack, immediate treatment with stents ...

Home March 05, 2023
Home
Subscribe Now